CRVO CervoMed Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1053691 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-99.9%
TTM net income YoY-11.5%
TTM EPS YoY—
Revenue 3-yr CAGR-87.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-334,924.9%
Net margin-326,822.5%
FCF margin—
EBITDA margin—
Returns
ROE-131.5%
ROA-109.8%
ROIC (approx.)-165.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.01M | $9.74M | $7.14M | $0 | — |
| R&D expense | $21.82M | $18.80M | $8.44M | $1.34M | $8.50M |
| SG&A expense | $10.48M | $9.17M | $6.52M | $2.14M | $7.45M |
| Operating income | -$28.29M | -$18.23M | -$7.81M | -$3.48M | -$24.68M |
| Interest expense | — | — | $0 | $587 | — |
| Pretax income | — | — | — | -$15.59M | -$24.54M |
| Income tax | $0 | — | — | $0 | -$443,893 |
| Net income | -$26.97M | -$16.29M | -$2.17M | -$5.80M | -$24.10M |
| EBITDA | — | — | — | -$3.48M | -$24.58M |
| EPS (basic) | -2.98 | -2.02 | -0.82 | -11.20 | -12.38 |
| EPS (diluted) | — | — | — | 2,038,891.00 | 1,946,859.00 |
| Balance sheet | |||||
| Cash & equivalents | $8.24M | $9.00M | $7.79M | $4.09M | $6.67M |
| Short-term investments | $12.63M | $29.92M | $0 | $12.41M | $0 |
| Current assets | $22.88M | $43.08M | $9.96M | $4.16M | $37.82M |
| PP&E, net | — | — | — | — | $0 |
| Total assets | $22.88M | $43.08M | $9.97M | $4.16M | $37.84M |
| Current liabilities | $4.66M | $3.88M | — | — | $2.93M |
| Total liabilities | $4.66M | $3.88M | $2.60M | $13.16M | $2.93M |
| Shareholders' equity | $18.22M | $39.20M | $7.38M | -$33.29M | $34.91M |
| Shares outstanding | 9.25M | 8.70M | 5.67M | 518,140 | 2.04M |
| Cash flow statement | |||||
| Operating cash flow | -$23.45M | -$16.53M | -$7.45M | -$2.57M | -$14.50M |
| Investing cash flow | $18.10M | -$28.66M | $0 | -$12.24M | $4,000 |
| Financing cash flow | $4.59M | $46.40M | $11.15M | $0 | $33.30M |
| Depreciation & amortization | — | — | — | $0 | $93,416 |
| Stock-based compensation | $1.45M | $1.41M | $407,632 | $333,835 | $897,260 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.